AveXis’ Gene Therapy AVXS-101 Edges Closer to Pivotal Trial for SMA Type 1 – SMA News Today
|
AveXis' Gene Therapy AVXS-101 Edges Closer to Pivotal Trial for SMA Type 1
SMA News Today AveXis is working with the U.S. Food and Drug Administration (FDA) to overcome final regulatory hurdles before starting a pivotal trial of AVXS-101 for the treatment of spinal muscular atrophy type 1 (SMA type 1) later in 2017. AVXS-101 is a gene … |
